AstraZeneca Annual Report and 84 Form 20-F Information 2005 CONSOLIDATED INCOME STATEMENT FOR THE YEAR ENDED 31 DECEMBER 2005 2004 2003 Notes $m $m $m Sales 23,950 21,426 18,849 Cost of sales 5,356 5,193 4,463 Distribution costs 211 177 162 Research and development 3,379 3,467 3,012 Selling, general and administrative costs 8,695 8,268 7,393 Other operating income 1 193 226 188 Operating profit 1 6,502 4,547 4,007 Profit on sale of interest in joint venture 2 219 Finance income 3 665 532 381 Finance expense 3 500 454 311 Profit before tax 6,667 4,844 4,077 Taxation 4 1,943 1,161 1,033 Profit for the period 4,724 3,683 3,044 Attributable to: Equity holders of the Company 4,706 3,664 3,022 Minority interests 20 18 19 22 Basic earnings per $0.25 Ordinary Share 5 $2.91 $2.18 $1.77 Diluted earnings per $0.25 Ordinary Share 5 $2.91 $2.18 $1.77 Weighted average number of Ordinary Shares in issue millions 5 1,617 1,673 1,709 Diluted average number of Ordinary Shares in issue millions 5 1,618 1,675 1,712 Dividends declared and paid in the period 21 1,676 1,408 1,244 All activities were in respect of continuing operations.
CONSOLIDATED STATEMENT OF RECOGNISED INCOME AND EXPENSE FOR THE YEAR ENDED 31 DECEMBER 2005 2004 2003 Notes $m $m $m Profit for the period 4,724 3,683 3,044 Foreign exchange adjustments on consolidation 18 1,052 744 1,267 Available for sale losses gains taken to equity 18 10 31 1 Actuarial loss for the period 18 35 179 240 Tax on items taken directly to reserves 4, 18 25 416 139 1,122 1,012 1,167 Total recognised income and expense for the period 3,602 4,695 4,211 Attributable to: Equity holders of the Company 3,595 4,690 4,186 Minority interests 7 525 Tax on items taken directly to reserves in 2004 includes a credit of $357m in respect of foreign exchange losses in 2000 Note 4.
$m means millions of US dollars
